At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 102 enrolled
Drug / intervention
Bendamustine hydrochloridedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-Label Study to Evaluate Bendamustine Hydrochloride in the Treatment of Chinese Patients With Indolent Non-Hodgkin Lymphoma (NHL) Refractory to Rituximab Treatment
Teva Branded Pharmaceutical Products R&D, Inc.·interventional·Posted May 11, 2012·Updated May 26, 2023
In Brief
A Phase 3 clinical trial evaluating Bendamustine hydrochloride for Non-Hodgkin Lymphoma. Completed, enrolled 102 participants across 27 sites.
Detailed Summary
The primary objective of the study is to determine the overall response rate (ORR), which includes complete response (CR) and partial response (PR), to bendamustine treatment in participants with indolent non-Hodgkin lymphoma (NHL) that has progressed after rituximab or a rituximab-containing therapy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon-Hodgkin Lymphoma
CountriesChina
Collaborators--
Timeline
Phase 3CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedMay 2012
Enrollment StartAug 2012
Primary CompletionJun 2015
Study CompletionApr 2017
TodayJul 2026
First PostedMay 11, 2012
Enrollment StartAug 6, 2012
Primary CompletionJun 18, 2015
Study CompletionApr 24, 2017
TodayJul 2, 2026
Enrollment to primary: 2.9 yearsPosted 14.1 years ago
Interventions
Bendamustine hydrochloridedrug
Bendamustine will be be administered per dose and schedule specified in the arm description.